Clinical Trial Update: Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes [Phase 2]

View source ↗

Summary

Phase II trial evaluating lymphodepleting conditioning plus anti-gp100:154-162 TCR-engineered lymphocytes in metastatic melanoma. The study was terminated and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• anti-gp100:154-162 TCR-engineered lymphocytes (gp100-specific TCR-engineered lymphocytes)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Skin Cancer, Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2012-12-04